A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2-early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)

被引：1
|
作者：
Hamilton, E. [1 ]
Loibl, S. [2 ]
Niikura, N. [3 ]
Rastogi, P. [4 ]
Saini, K. S. [5 ]
Gioni, I. [6 ]
Klinowska, T. [6 ]
Mayer, I. [7 ]
Stuart, M. [6 ]
Syta, E. [8 ]
Walding, A. [6 ]
Bachelot, T. [9 ]
机构：
[1] Sarah Cannon Res Inst Tennessee Oncol, Med Oncol Dept, Nashville, TN USA
[2] German Breast Grp GBG Forschungs GmbH, Med & Res Dept, Neu Isenburg, Germany
[3] Tokai Univ, Sch Med, Breast Oncol Dept, Isehara, Kanagawa, Japan
[4] Univ Pittsburgh, Oncol Dept, Pittsburgh, PA USA
[5] Fortrea Inc, Global Clin Dev, Durham, NC USA
[6] AstraZeneca, Late Dev Oncol R&D, Cambridge, England
[7] AstraZeneca, Late Dev Oncol R&D, Gaithersburg, MD USA
[8] AstraZeneca Canada Inc, Late Dev Oncol, Toronto, ON, Canada
[9] Ctr Leon Berard, Med Oncol Dept, Lyon, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.3100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
354TiP
引用
收藏
页码：S323 / S324
页数：2
相关论文
共 50 条
  • [1] A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2-early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)
    Hamilton, Erika
    Loibl, Sibylle
    Niikura, Naoki
    Rastogi, Priya
    Saini, Kamal S.
    Gioni, Ioanna
    Klinowska, Teresa
    Mayer, Ingrid A.
    Stuart, Mary
    Syta, Emilia
    Walding, Andrew
    Bachelot, Thomas
    CANCER RESEARCH, 2024, 84 (09)
  • [2] CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2-early breast cancer
    Hamilton, Erika P.
    Loibl, Sibylle
    Bachelot, Thomas
    Gnant, Michael
    Niikura, Naoki
    Park, Yeon Hee
    Tolaney, Sara M.
    Pistilli, Barbara
    Rastogi, Priya
    Saini, Kamal S.
    Gioni, Ioanna
    Johnston, Simon
    Nunes, Raquel
    Quintana, Angela
    Stuart, Mary
    Syta, Emilia
    Walding, Andrew
    Klinowska, Teresa
    Mayer, Ingrid A.
    FUTURE ONCOLOGY, 2025, 21 (07) : 795 - 806
  • [3] A Phase 3, randomized, open-label study of upfront camizestrant vs standard endocrine therapy as adjuvant treatment for ER-positive/HER2negative early breast cancer with intermediate-high or high risk of recurrence (CAMBRIA-2)
    Loibl, Sibylle
    Park, Yeon
    Tolaney, Sara
    Gioni, Ioanna
    Johnston, Simon
    Klinowska, Teresa
    Mayer, Ingrid A.
    Nunes, Raquel
    Pistilli, Barbara
    Stuart, Mary
    Quintana, Angela
    Walding, Andrew
    Gnant, Michael
    CANCER RESEARCH, 2024, 84 (09)
  • [4] EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2-early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET
    Jhaveri, Komal
    O'Shaughnessy, Joyce
    Andre, Fabrice
    Goetz, Matthew P.
    Harbeck, Nadia
    Martin, Miguel
    Bidard, Francois-Clement
    Thomas, Zachary M.
    Young, Suzanne
    Ismail-Khan, Roohi
    Smyth, Lillian M.
    Gnant, Michael
    CANCER RESEARCH, 2023, 83 (05)
  • [5] Adaptlate -a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker - adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, hr+/her2-early breast cancer
    Gluz, Oleg
    Degenhardt, Tom
    Marschner, Norbert
    Christgen, Matthias
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    Kates, Ronald
    Schinkoethe, Timo
    Graeser, Monika
    Wurstlein, Rachel
    Kuemmel, Sherko
    Harbeck, Nadia
    CANCER RESEARCH, 2021, 81 (04)
  • [6] ELEGANT: Elacestrant vs Standard ET in Women and Men With Node-positive, ER+, HER2-Early Breast Cancer (eBC) With High Risk of Recurrence - A Global, Multicenter, Randomized, Open- label Phase 3 Study
    Bardia, A.
    Kaklamani, V.
    O'Shaughnessy, J.
    Schmid, P.
    Beck, J. T.
    De Laurentiis, M.
    Curigliano, G.
    Rugo, H.
    Barcenas, C. H.
    Gradishar, W. J.
    Ignatiadis, M.
    Cameron, D. A.
    Tonini, G.
    Scartoni, S.
    Crozier, J.
    Nicacio, L. V.
    Wasserman, T.
    Tolaney, S. M.
    BREAST, 2025, 80
  • [7] ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker-Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2-early breast cancer.
    Gluz, Oleg
    Scheffen, Iris
    Degenhardt, Tom
    Marschner, Norbert Walter
    Christgen, Matthias
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    Kates, Ronald E.
    Schinkoethe, Timo
    Graeser, Monika Karla
    Wuerstlein, Rachel
    Kuemmel, Sherko
    Bauer, Lelia
    Schem, Christian
    Fehm, Tanja N.
    Neubauer, Hans
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2-breast cancer
    Rastogi, Priya
    Toi, Masakazu
    Harbeck, Nadia
    Bourayou, Nawel
    Frenzel, Martin
    Johnston, Stephen
    CANCER RESEARCH, 2018, 78 (04)
  • [9] PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone HR1/HER2-early breast cancer
    Mayer, E. L.
    Demichele, A. M.
    Pfeiler, G.
    Barry, W.
    Metzger, O.
    Rastogi, P.
    Symmans, F.
    Burstein, H. J.
    Miller, K.
    Loibl, S.
    Schmatloch, S.
    Goulioti, T.
    Zardavas, D.
    Fesl, C.
    Koehler, M.
    Bartlett, C. Huang
    Huang, X.
    Piccart, M.
    Winer, E.
    Gnant, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Open-label phase II study of everolimus plus endocrine therapy in postmenopausal women with ER+, HER2-metastatic breast cancer (Chloe trial)
    Shien, Tadahiko
    Kitada, Masahiro
    Uemura, Yukari
    Kato, Hiroaki
    Kikawa, Yuichiro
    Shimomura, Akihiko
    Watanabe, Kenichi
    Kojima, Yasuyuki
    Yokota, Toru
    Kamei, Yoshiaki
    Nishimura, Reiki
    Nagashima, Takeshi
    Hashimoto, Naoki
    Sakaguchi, Koichi
    Yamashita, Toshinari
    Harano, Kenichi
    Yonemori, Kan
    Horimoto, Yoshiya
    Mukai, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345